These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 25391374)

  • 1. Insulin-like growth factor-1 receptor signaling increases the invasive potential of human epidermal growth factor receptor 2-overexpressing breast cancer cells via Src-focal adhesion kinase and forkhead box protein M1.
    Sanabria-Figueroa E; Donnelly SM; Foy KC; Buss MC; Castellino RC; Paplomata E; Taliaferro-Smith L; Kaumaya PT; Nahta R
    Mol Pharmacol; 2015 Feb; 87(2):150-61. PubMed ID: 25391374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin).
    Oliveras-Ferraros C; Vazquez-Martin A; Martin-Castilló B; Pérez-Martínez MC; Cufí S; Del Barco S; Bernado L; Brunet J; López-Bonet E; Menendez JA
    Int J Oncol; 2010 Sep; 37(3):669-78. PubMed ID: 20664936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Superior antitumor activity of a novel bispecific antibody cotargeting human epidermal growth factor receptor 2 and type I insulin-like growth factor receptor.
    Chen C; Zhang Y; Zhang Y; Li J; Tsao SW; Zhang MY
    Mol Cancer Ther; 2014 Jan; 13(1):90-100. PubMed ID: 24227890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells.
    Camirand A; Lu Y; Pollak M
    Med Sci Monit; 2002 Dec; 8(12):BR521-6. PubMed ID: 12503030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells.
    Lyu H; Yang XH; Edgerton SM; Thor AD; Wu X; He Z; Liu B
    Oncotarget; 2016 Jan; 7(3):2921-35. PubMed ID: 26621843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MEK inhibition increases lapatinib sensitivity via modulation of FOXM1.
    Gayle SS; Castellino RC; Buss MC; Nahta R
    Curr Med Chem; 2013; 20(19):2486-99. PubMed ID: 23531216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the Insulin-like Growth Factor Receptor Pathway in Patients with Advanced Breast Cancer Treated with Trastuzumab.
    Christodoulou C; Oikonomopoulos G; Koliou GA; Kostopoulos I; Kotoula V; Bobos M; Pentheroudakis G; Lazaridis G; Skondra M; Chrisafi S; Koutras A; Bafaloukos D; Razis E; Papadopoulou K; Papakostas P; Kalofonos HP; Pectasides D; Skarlos P; Kalogeras KT; Fountzilas G
    Cancer Genomics Proteomics; 2018; 15(6):461-471. PubMed ID: 30343280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells.
    Zavodovskaya M; Campbell MJ; Maddux BA; Shiry L; Allan G; Hodges L; Kushner P; Kerner JA; Youngren JF; Goldfine ID
    J Cell Biochem; 2008 Feb; 103(2):624-35. PubMed ID: 17562544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer.
    Francis RE; Myatt SS; Krol J; Hartman J; Peck B; McGovern UB; Wang J; Guest SK; Filipovic A; Gojis O; Palmieri C; Peston D; Shousha S; Yu Q; Sicinski P; Coombes RC; Lam EW
    Int J Oncol; 2009 Jul; 35(1):57-68. PubMed ID: 19513552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer.
    Köstler WJ; Hudelist G; Rabitsch W; Czerwenka K; Müller R; Singer CF; Zielinski CC
    J Cancer Res Clin Oncol; 2006 Jan; 132(1):9-18. PubMed ID: 16184380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
    Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
    Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inactivation of Rac1 reduces Trastuzumab resistance in PTEN deficient and insulin-like growth factor I receptor overexpressing human breast cancer SKBR3 cells.
    Zhao Y; Wang Z; Jiang Y; Yang C
    Cancer Lett; 2011 Dec; 313(1):54-63. PubMed ID: 21943825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
    Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
    Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disruption of FOXO3a-miRNA feedback inhibition of IGF2/IGF-1R/IRS1 signaling confers Herceptin resistance in HER2-positive breast cancer.
    Luo L; Zhang Z; Qiu N; Ling L; Jia X; Song Y; Li H; Li J; Lyu H; Liu H; He Z; Liu B; Zheng G
    Nat Commun; 2021 May; 12(1):2699. PubMed ID: 33976188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin-like growth factor-1 receptor as a novel prognostic marker and its implication as a cotarget in the treatment of human adenocarcinoma of the esophagus.
    Kalinina T; Bockhorn M; Kaifi JT; Thieltges S; Güngör C; Effenberger KE; Strelow A; Reichelt U; Sauter G; Pantel K; Izbicki JR; Yekebas EF
    Int J Cancer; 2010 Oct; 127(8):1931-40. PubMed ID: 20104520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance.
    Mitra D; Brumlik MJ; Okamgba SU; Zhu Y; Duplessis TT; Parvani JG; Lesko SM; Brogi E; Jones FE
    Mol Cancer Ther; 2009 Aug; 8(8):2152-62. PubMed ID: 19671734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions.
    Liu B; Fan Z; Edgerton SM; Yang X; Lind SE; Thor AD
    Cell Cycle; 2011 Sep; 10(17):2959-66. PubMed ID: 21862872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells.
    Joshi JP; Brown NE; Griner SE; Nahta R
    Biochem Pharmacol; 2011 Nov; 82(9):1090-9. PubMed ID: 21803025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. t-Darpp Activates IGF-1R Signaling to Regulate Glucose Metabolism in Trastuzumab-Resistant Breast Cancer Cells.
    Lenz G; Hamilton A; Geng S; Hong T; Kalkum M; Momand J; Kane SE; Huss JM
    Clin Cancer Res; 2018 Mar; 24(5):1216-1226. PubMed ID: 29180608
    [No Abstract]   [Full Text] [Related]  

  • 20. Transforming growth factor beta induces clustering of HER2 and integrins by activating Src-focal adhesion kinase and receptor association to the cytoskeleton.
    Wang SE; Xiang B; Zent R; Quaranta V; Pozzi A; Arteaga CL
    Cancer Res; 2009 Jan; 69(2):475-82. PubMed ID: 19147560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.